Skip to main content

cancer immunotherapy Archives

Data haul improves immunotherapy response prediction

Jan. 16, 2024—Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

Read more


Clinical trial shows efficacy for atezolizumab combined with carboplatin

Dec. 15, 2023—by Tom Wilemon Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best. Vanderbilt researchers led a clinical trial combining atezolizumab, an...

Read more


Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Aug. 3, 2023—Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

Read more


Nanoparticles boost anti-cancer immunity

Aug. 16, 2022—An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

Read more


Couple’s gift helps support immunotherapy research

Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

Read more


Breast cancer cells ‘steal’ nutrients from immune cells: study

Apr. 1, 2021—Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

Read more


A “torque” for tumor blood vessels

Aug. 20, 2020—Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.

Read more


Potential new cancer target

Jun. 4, 2020—Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

Read more


Patient’s cancer treatment includes new immunotherapy

Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.

Read more


New prostate cancer treatment concept

Aug. 22, 2019—Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Read more


Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Read more


Discovery points to new cancer immunotherapy option

Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more